{"name":"ONL Therapeutics","slug":"onl-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Avacincaptad Pegol intravitreal solution","genericName":"Avacincaptad Pegol intravitreal solution","slug":"avacincaptad-pegol-intravitreal-solution","indication":"Treatment of neovascular (wet) age-related macular degeneration","status":"phase_2"}]}],"pipeline":[{"name":"Avacincaptad Pegol intravitreal solution","genericName":"Avacincaptad Pegol intravitreal solution","slug":"avacincaptad-pegol-intravitreal-solution","phase":"phase_2","mechanism":"Avacincaptad pegol is an anti-vascular endothelial growth factor (VEGF) agent.","indications":["Treatment of neovascular (wet) age-related macular degeneration"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi2wJBVV95cUxNSUYwSExDMGQ5SjlTSHBuTjByV2pCV0FvM2lfcE5qejRvUTRzZzhJd0J4MXZxS0I2NjZwRlFTSFc5V0hpczBNNGpfc2ZNV2IzbExlWW9tQkRoSkRIbWJoRm9tR1hpUGVGajQ5ZXd2Rk5MNk9Xd2FQcVlXRnVjNDZKZzBvQnpRV0ExdUpFUERwNEg3VEg4NUZ2a1BKanNiSzdrOUlpOUhxeWoyMTE4c0k0VldlRDFrOXlNR3B1Ym0yMnJRMkp0WVFNRUJINXhMamhOTi10T0RzYVFEMkNBVFJsUWdsZkZDVXhvVmJGSUJ2am40dEt0RkxmRGp6NUxYYjZqUGdtVEtjczhkS3lXNkZkWkpJQW9peFJLRmRqcmdWNTV6TG9CLUZJcTRIR0NsV2E0NzZNNW9WaWs4eDZuMzVBZlJONk5FeDBJTWxkeDZKSlR5OE81eldQemlSdw?oc=5","date":"2026-03-16","type":"trial","source":"prnewswire.com","summary":"ONL Therapeutics Announces First European Patient Randomized in its Global Phase 2 GALAXY Trial of Xelafaslatide (ONL1204) in Patients with Geographic Atrophy (GA) Associated with Dry AMD - prnewswire","headline":"ONL Therapeutics Announces First European Patient Randomized in its Global Phase 2 GALAXY Trial of Xelafaslatide (ONL120","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxORzRoSDUwVUVZeG0tQWN6TjVkc2J2SW5YbE1OWXZKLWJHd1lTaC1EOFFkVVFXbDNYVFZnUThESHpycE5ROVd2TFhWYnlTUEc4VTVMYW9rMFRla0thUHZvRUZ5eS02LVVJc2YxNUNWUTZqeFplM1Y2b21STUZyMHlXTF9tNDJGUTNkNW1HUFF4QlMwU3JuM0hoSTdveVdGd3o4aHpUbmhjQzRzSjN1RXhnZ3lsLTFlWFJzU1ZVLTE2dFkxNXRadUktZnpiQkh6X2ZJNU5PWS1YUjA4emJTVFZMNkpPVDNaeDdad2pBT1pIeXc2UQ?oc=5","date":"2026-02-24","type":"trial","source":"Barchart.com","summary":"Dry AMD Clinical Trial Pipeline Gains Momentum: 70+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Barchart.com","headline":"Dry AMD Clinical Trial Pipeline Gains Momentum: 70+ Companies Lead the Charge in Pioneering New Treatments | DelveInsigh","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxON09LODc5SjZkZmlUNjFMampTLUJVdTZ4WXY0NEFZaDRyY3hUVmU0ZUtwNHZWeWhzNGFjaGk0X3BxbDFZRzMyRlpJZVh4MVBzak9yX0NVM2N2VFYwN09KMXpBTVhpNTJGVGs5dXBmZjBybjBRdkxibk1LT1hEVkw5X09mUHcxTF81ak1STWhMMzJvZndH?oc=5","date":"2026-01-14","type":"pipeline","source":"BioPharma Dive","summary":"JPM26: Paying cash for obesity drugs, renewed IPO optimism and pharma’s cell therapy view - BioPharma Dive","headline":"JPM26: Paying cash for obesity drugs, renewed IPO optimism and pharma’s cell therapy view","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywJBVV95cUxNal9yb0poS19QYmQ1U3N3bGFzYXJ3VVFoNFZ1bFBEbWFTRGIwbmZOcVdqR0JaSWtsNjR1dVhjNzRaVFJLUzJBSDQtRUpha1VkNW9WSDdlY3pOd2FHeTRHXzhtUEZwMlJYSWFoWUhucWQ1eWdtTEkxNzR1MHlrSGpvUnBkZVE0ODlWQVpoRWhBS19iSUlXY3FsemVFd0xzV2RmOV91MUxSZ2NoWTFnNjFqQXF1QW83YzRTNDZlZ0FNYmZha1dGRjVNbzViMldQSXdyRXl6V1EtVmdRYlZOZHZuTnVQU2ZZR1NZQ0hqRmpuZkw1X09uRHMzd0duNlpOZlhULWMzRnVlajBBb3g0OWJYQnExeGNMc2ZqZHFuMld5YmFObkVMZFF0VXJLT3BpRVRFM3ZUS2Q4TGw4TDhLUUhGS1V4VU1kbS00Q0NR?oc=5","date":"2025-12-01","type":"pipeline","source":"GlobeNewswire","summary":"Geographic Atrophy Market to Surge Significantly During the - GlobeNewswire","headline":"Geographic Atrophy Market to Surge Significantly During the","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOT0otTnQ1QW92dXB2UW1fdDNmQmNVUGlIWWVKZFBxbFZqNXNTSjAyNExEUUpLREZfZHJwaFk2NlVaaThNZGZlYjcwSWFLblZHcUV4bVNFS0d2bXVnaDZ0QVJlVklDcXFWV05GNUx3MHo1V1BCTnB6UmxxWTF2dG9BdTVwclVRTWwwNnpmV2VmQXhZOHMtN0E?oc=5","date":"2025-11-26","type":"pipeline","source":"Medical Marketing and Media","summary":"Rx Rundown: Novo Nordisk, Mayne Pharma, Quarry Thera and more - Medical Marketing and Media","headline":"Rx Rundown: Novo Nordisk, Mayne Pharma, Quarry Thera and more","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxOWlMyanVwZ1VYQ2xpVXZQRUluWldaWkthUDN4SF9md0JIT3JLTmlyX3I1SFFYSmJTNVlZS3hUWDVsWFFEMktOUW01bHNJNHFrd2JlOVNrN0l0OEVtSGNLazExN3VEX0h0M0c4ZjNDdlVmSVZWbHdKZm9Rb0pIWmNyZDRxREpxNk0?oc=5","date":"2025-11-11","type":"pipeline","source":"Yahoo Finance","summary":"Turn Therapeutics’ GX-03 Technology Named as One of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine - Yahoo Finance","headline":"Turn Therapeutics’ GX-03 Technology Named as One of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Pat","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gJBVV95cUxPNnpiZEdUU2FkcmxmUGtsdVNIYWZuUFpZdU9aMTRYaE1SMzNacU9ZU2JyQlM3SWctMUZWdXhBOW5VZzlMTkNxbnJ1OGl4MHpqTG12X2t0ZGl4Y1hUaTRycWxqTjA4MWhDaU9makY3YTh2Tk5HYzlnVzVMczVGS0JGU240VVJHRTlEMVRyc0trSWFreHhrLVNRVV9ZRDdjS2JBZGhXcjFQRDg0NU1LVWJCYV9DZ0ZBN2kydXVEeVgyM0xRZjllSTJIZ2E2QjZwYURuUEN0eTVHZFBnejRNNUFBaUJnWjlGVFM2czNjTkxMWE9rMDhjZ0xWQzdUOEZRZ1hLcy1DQ3Y4VXl0ZmZiQkZmU2ZWZE9Zc2c5MG5TeGNiVjh3SXM0bGdGME91X3hxWEQ0T19EVE5CSkViWThlRHZKQUJiOTY1akR0ZVJhaXVBWjlwUQ?oc=5","date":"2025-11-10","type":"pipeline","source":"GlobeNewswire","summary":"ONL Therapeutics to Present at EYENOVATE and the FLORetina–ICOOR Congress 2025 - GlobeNewswire","headline":"ONL Therapeutics to Present at EYENOVATE and the FLORetina–ICOOR Congress 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOMzJaZDZ3SzFyRnh1d0JNYldIc3ZETUlZT0U3blRtaE42TFBUek4zQnhyVVFLYlkwX2JZT2dPVER2eURVZVBuWU1fM1V3QjgtSUtpanduTWVhSlBIOVJuN2x4bFhfakxoaktmNzFIMnVrelBYTS1fVG9oSGM0eURub0N5bk51MHNEamduY1VtbmRoTnRNb2N0eE5xbUw2NHdXNTY2OQ?oc=5","date":"2025-09-18","type":"pipeline","source":"Global Venturing","summary":"Nakada retires from investor role at pharma group Johnson & Johnson - Global Venturing","headline":"Nakada retires from investor role at pharma group Johnson & Johnson","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTFA3RVpxRzRqUXN6QUU4Y2FqQllJNTlJRW90VnFTWmZ1Ui1wWkRUV1lCc0tjMnRabzVZVmt4SWlhMUZYVlNab2d2bXcteGFVMXNmclYxZnpVVVVmX3NhRS04S0JHOHZncUlj?oc=5","date":"2025-08-21","type":"pipeline","source":"Wiley Online Library","summary":"Editorial: Redefining Decompensation in Cirrhosis—More Than an Academic Playground? Authors' Reply - Wiley Online Library","headline":"Editorial: Redefining Decompensation in Cirrhosis—More Than an Academic Playground? Authors' Reply","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxNQ0tVa2pCR1BtbjhUcld6anVwN3pxMkhmOGQ4QVhYeXplSVF2Z1liR0NrYjhScDZ6bkdFSnE0d09uQS1kcEVBclR0bmN0cG95YnplZW5feEx4MVkzaUp5NUhzWUljOFJ1SDJVVkwwM1NuYWdaelc4dlZPajZJTlB1Sm5MSkhEbnloRUhRbllXcWpFdzVMcWUxNS1JRWxyNUNlMmNVcE5wcFI4YzAtNUY1UmpnMkYxcEVZeVozS0wzTXB4eFBhcU5TeWNLUXVUbWFXMm1INTg4UnJ0ZTQ?oc=5","date":"2025-07-31","type":"regulatory","source":"LENZ Therapeutics","summary":"LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia - LENZ Therapeutics","headline":"LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQX1JmT1BYMmNQMFptX296SjZTUEdIdGZIZUNrRTEtR1A2TjBaOXdtSkR2cFVrSjc4X01ZNzBaQzg0cDNkcjljWGZpclZaWnhYeFY0N21xQzJodVRva0ZjWTdKellJeWRIdDN6cFZpQnNhZ0RzdFZUWGVJSXp4TFdMZ0dEajMwVW5EcXJaX2pVekV1U002dDVRRjJ5QlR0MTI3aTlhM1UxQ3JkNWw1SDZpMmlB?oc=5","date":"2023-11-01","type":"pipeline","source":"Pharmaceutical Technology","summary":"ONL Therapeutics seeks upto $100m to further eye disease pipeline - Pharmaceutical Technology","headline":"ONL Therapeutics seeks upto $100m to further eye disease pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE9tSFloRnVrYlVQOVJ6TFpDVFdRY1RlQ05RVkdFN1puc242OUVVY05pM3c5clJ3ZldLS0ZXdm9nakpabElLZTcyNll4dFlTUkFtblp4Z003RlVvZnJKWlJwRzJZUGlSUEtRRVNHbW1hOVpxZGtEQTJLbA?oc=5","date":"2023-03-09","type":"trial","source":"Clinical Trials Arena","summary":"ONL Therapeutics closes first tranche of financing for trial of ONL1204 - Clinical Trials Arena","headline":"ONL Therapeutics closes first tranche of financing for trial of ONL1204","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}